We are a Swedish biotechnology company with a global presence, offering cell culture matrices intended for culturing of primary cells. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture based research. The company was established in 2008 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has 15 employees spanning from production, R&D, logistics, sales and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.
BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality.
We offer an expansive portfolio of chemically defined and xeno-free laminin proteins for a variety of applications, including reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types, such as hepatocytes, skeletal muscle cells and different neural cells. The impact of our laminin matrices on cell culture quality has been scientifically validated in many high-impact journals.
BioLamina is a company in constant development and progress, and we truly believe our strength comes from our employees. It is therefore very important for us to find people who share our vision and values, and want to be part of creating the next generation of regenerative therapies.
If you are interested in knowing more about us and what being part of the BioLamina team would mean, don’t hesitate to contact us at career@biolamina.com
Students
BioLamina is a research-based company and we know and value the knowledge that resides in the young and vital university community. Therefore, we are always open to have a dialogue with students who want and need to get “real life” practice.
BioLamina Newsletters
Corning introduces laminin-521 cultureware products
Corning has developed Corning® PureCoat™ rLaminin-521 cultureware products for stem cell research, by combining BioLamina’s expertise in rLaminin-521 expression with Corning’s proprietary surface coating technology.
CORNING, N.Y., Corning Incorporated, April 20, 2016
_________________________________________________________________
BioLamina utökar globalt - tecknar flera distributionsavtal
ThermoFisher, Corning, Stem Cell Technologies och ESI-Bio, kommer nu att sälja LN521 som en del av sin cell kultiverings portfölj via sina försäljningskanaler.
BioLamina, Stockholm, February 2, 2016
_________________________________________________________________________
Liver cell therapies closer as study reveals key to mass production
Stem cell scientists have made a key find that aids the quest to produce therapies for patients with liver damage. They have developed a new technique for growing liver cells from stem cells that is cost-effective and could be adapted for mass production of clinical grade cells.
MRC Centre for Regenerative Medicine, Edinburgh, UK, November 25, 2015
__________________________________________________________________________
Production of recombinant laminins for ex vivo cell therapies
CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies. First commercial CAP(R)Go-derived laminin, LN521, expected to be globally available in 2016.
Dow Jones Newswire Web, October 28, 2015
__________________________________________________________________________
BioLamina engages Dr. Stephen Minger as Scientific Advisor
BioLamina’s long-term goal is to provide a portfolio of high quality, easy to use, products and services for primary cell culture within research, drug discovery models and cell therapy. To reach this goal, BioLamina needs to focus on the right products and deliver them with the right quality. Dr. Minger’s role will be to help direct and prioritize this work, to ensure release of quality products in a timely fashion. He will work closely with our scientists and executive management.
BioLamina, Stockholm, Sweden, September 28, 2015
__________________________________________________________________________
Corning Announces New Agreement with BioLamina
More comprehensive and scalable culture solution made available to Corning’s global customer base.
CORNING, N.Y., September 11, 2014
BioLamina tar täten när stamcellsfältet öppnas
A new method makes it possible to culture large amounts embryonic stem cells without destroying the embryo. This method can give more than 400 kilos of stem cells in a month at the same time as it avoids any ethical issues related to stem cell research.
Life Science Sweden, January, 2014
BioLamina is recruiting three new members
The Stockholm based research company BioLamina is strengthening its position through recruting three new members: Camilla Myhre Sandberg, Anders Blom och Fredrik Mattsson.
Life Science Sweden, November, 2013
Laminin article in GEN Biotech
In this article Dr. Karl Tryggvason discuss the use of biologically relevant human recombinant laminins from BioLamina that successfully recreate specific cell niches in the cell culture dish. This enables robust cell cultivation in highly physiological microenvironments that practically solves all current technical challenges with stem cell culture.
GEN Biotech, May, 2013
BioLamina ranked as one of 24 hottest startups in Sweden
BioLamina listed as the only biotech among Sweden's 24 most promising startups in Sweden.
Veckans Affärer, April 18, 2013
BioLamina listed as Sweden's 33 most successful startups
BioLamina ranked as on of Swedens 33 hottest technology companies, 3rd year in a row.
NyTeknik, April 16, 2013
